Source: International Congress 2019 – ALERT: Abstracts Leading to Evolution in Respiratory Medicine Trials: Interstitial lung diseases and pulmonary hypertension
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
K. Highland (Cleveland, Ohio, United States of America), A. Azuma (Tokyo, Japan), A. Fischer (Denver, Colorado, United States of America), M. Kuwana (Tokyo, Japan), T. Maher (London , United Kingdom), M. Mayes (Houston, Texas, United States of America), G. Raghu (Seattle, United States of America), M. Girard (Reims, France), M. Alves (Ingelheim am Rhein, Germany), M. Gahlemann (Basel , Switzerland), O. Distler (Zurich, Switzerland). Changes in FVC in the SENSCIS trial of nintedanib in patients with systemic sclerosis-associated ILD (SSc-ILD). 1882

Member's Comments

No comment yet.

Related content which might interest you: Effects of nintedanib in patients with systemic sclerosis-associated ILD (SSc-ILD) and differing FVC at baseline: the SENSCIS trial Source: International Congress 2019 – Connective tissue disease-associated interstitial lung disease and hypersensitivity pneumonitis: what’s new? Year: 2019 Dose adjustments in the SENSCIS trial of nintedanib in patients with systemic sclerosis-associated ILD (SSc-ILD) Source: International Congress 2019 – Assessment and management of immune-mediated interstitial lung diseases Year: 2019 Effects of nintedanib in patients with systemic sclerosis-associated ILD (SSc-ILD) and differing extents of lung fibrosis: the SENSCIS trial Source: International Congress 2019 – From biomarkers to treatment of immune-mediated interstitial lung disease: what’s new? Year: 2019 Effects of nintedanib in patients with progressive fibrosing ILDs and differing baseline FVC: further analyses of the INBUILD trial Source: Virtual Congress 2020 – What is new in interstitial lung diseases of known origin? Year: 2020 Interstitial lung disease (ILD) in patients with polymyositis/dermatomyositis (PM/DM): clinical features and response to treatment in 6 cases Source: Eur Respir J 2001; 18: Suppl. 33, 528s Year: 2001 Effect of baseline FVC on lung function decline with nintedanib in patients with IPF Source: International Congress 2015 – Treatment of IPF Year: 2015 Clinico-laboratory characteristics of patients with interstitial lung disease (ILD) in polymyositis-dermatomyositis (PM/DM) Source: Eur Respir J 2003; 22: Suppl. 45, 46s Year: 2003 Changes in biomarkers in patients with idiopathic pulmonary fibrosis (IPF) treated with nintedanib and sildenafil Source: International Congress 2019 – The evolving field of idiopathic interstitial pneumonia Year: 2019 Long-term safety of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF): Pooled analysis of 4 clinical trials Source: International Congress 2016 – IPF treatment I Year: 2016 Nintedanib plus sildenafil in patients with idiopathic pulmonary fibrosis (IPF): the INSTAGE trial Source: International Congress 2018 – Clinical news in idiopathic interstitial pneumonias Year: 2018 Safety and tolerability of pirfenidone (PFD) in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD)–The LOTUSS study Source: International Congress 2015 – New frontiers in the management of interstitial and orphan lung diseases Year: 2015 Interstitial lung disease with ANCA-associated vasculitis (AAV-ILD): Clinical features and survival compared to patients with ILD associated with systemic sclerosis and IPF Source: Virtual Congress 2020 – Addressing unresolved questions in rare diffuse parenchymal lung diseases: interdisciplinary research is the key Year: 2020 Does nintedanib have the same effect on FVC decline in patients with progressive fibrosing ILDs treated with DMARDs or glucocorticoids? Source: Virtual Congress 2020 – What is new in interstitial lung diseases of known origin? Year: 2020 Proteomic analysis of BALf in systemic sclerosis patients (SSp) with or without pulmonary fibrosis (ILD) Source: Eur Respir J 2005; 26: Suppl. 49, 202s Year: 2005 Analysis of patients with idiopathic pulmonary fibrosis (IPF) with percent predicted forced vital capacity (FVC)<50% treated with pirfenidone (PFD) in RECAP Source: International Congress 2016 – IPF treatment I Year: 2016 Effect of baseline corticosteroid medication on reduction in FVC decline with nintedanib Source: International Congress 2015 – Treatment of IPF Year: 2015 FVC decline in patients with SSc-ILD by use of anti-acid therapy Source: Virtual Congress 2020 – Addressing unresolved questions in rare diffuse parenchymal lung diseases: interdisciplinary research is the key Year: 2020 Lung function preservation in a phase 3 trial of tocilizumab (TCZ) in systemic sclerosis (SSc) Source: International Congress 2019 – ALERT: Abstracts Leading to Evolution in Respiratory Medicine Trials: Interstitial lung diseases and pulmonary hypertension Year: 2019 Quality of spirometry and diffusion of the lung (DLCO) data in patients with systemic sclerosis. Source: International Congress 2019 – Insights into physiological diagnostic services Year: 2019 Changes in biomarkers with nintedanib plus sildenafil in subjects with IPF by presence of emphysema in the INSTAGE trial Source: Virtual Congress 2020 – Promising biomarkers for idiopathic interstitial pneumonia Year: 2020